We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+30%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.83%
AUM
$1.29B
AUM Growth
+$370M
Cap. Flow
+$32.1M
Cap. Flow %
2.48%
Top 10 Hldgs %
19.69%
Holding
198
New
29
Increased
74
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$20.7M
2
AVTR icon
Avantor
AVTR
+$14.9M
3
TGTX icon
TG Therapeutics
TGTX
+$13.5M
4
CELL
PhenomeX Inc. Common Stock
CELL
+$11.4M
5
TXG icon
10x Genomics
TXG
+$10.3M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.9M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$17.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.4M
4
PEN icon
Penumbra
PEN
+$10.1M
5
TWST icon
Twist Bioscience
TWST
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 48.02%
2 Technology 12.16%
3 Consumer Discretionary 8.78%
4 Industrials 6.66%
5 Financials 5.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESTC icon
26
Elastic
ESTC
$7.81B
$15.1M 1.16%
103,080
+21,944
+27% +$2.7M
VEEV icon
27
Veeva Systems
VEEV
$37.4B
$15M 1.16%
55,060
– –
DCPH
28
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$14.9M 1.15%
260,798
+43,815
+20% +$2.6M
KRYS icon
29
Krystal Biotech
KRYS
$9.66B
$14M 1.08%
233,543
+11,121
+5% +$555K
SILK
30
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$13.8M 1.07%
219,483
+457
+0.2% +$28.4K
SRPT icon
31
Sarepta Therapeutics
SRPT
$1.77B
$13.5M 1.04%
78,970
+4,558
+6% +$675K
ITCI
32
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.4M 0.96%
390,289
-67,431
-15% -$1.77M
AFIB
33
DELISTED
Acutus Medical Inc
AFIB
$12.3M 0.95%
425,415
+104,788
+33% +$2.84M
PODD icon
34
Insulet
PODD
$9.79B
$12.2M 0.94%
47,695
+2,957
+7% +$734K
ZLAB icon
35
Zai Lab
ZLAB
$2.62B
$12M 0.93%
+88,871
New +$9.05M
KTB icon
36
Kontoor Brands
KTB
$4.26B
$11.8M 0.91%
290,212
+68,931
+31% +$2.54M
TFII icon
37
TFI International
TFII
$11.5B
$11.8M 0.91%
228,154
-5,228
-2% -$260K
TRIL
38
DELISTED
Trillium Therapeutics Inc.
TRIL
$11.3M 0.87%
767,384
+193,755
+34% +$2.79M
CALY
39
Callaway Golf Company
CALY
$3.14B
$11.2M 0.86%
465,315
+29,979
+7% +$612K
IIPR icon
40
Innovative Industrial Properties
IIPR
$1.72B
$11.1M 0.86%
60,693
-9,528
-14% -$1.43M
COUP
41
DELISTED
Coupa Software Incorporated
COUP
$10.9M 0.84%
32,077
+11,288
+54% +$3.49M
CVX icon
42
Chevron
CVX
$366B
$10.2M 0.79%
+120,938
New +$9.79M
TXG icon
43
10x Genomics
TXG
$6.61B
$10M 0.78%
+70,915
New +$10.3M
WSC icon
44
WillScot Mobile Mini Holdings
WSC
$4.41B
$9.81M 0.76%
423,478
+276,222
+188% +$5.57M
BAC icon
45
Bank of America
BAC
$442B
$9.53M 0.74%
+314,428
New +$8.43M
ARES icon
46
Ares Management
ARES
$30.9B
$9.41M 0.73%
+200,000
New +$9.05M
CHGG icon
47
Chegg
CHGG
$102M
$9.36M 0.72%
103,659
+445
+0.4% +$35.4K
HOUS
48
DELISTED
Anywhere Real Estate
HOUS
$9.32M 0.72%
710,151
+2,907
+0.4% +$34.7K
AMRC icon
49
Ameresco
AMRC
$1.36B
$8.8M 0.68%
168,393
-56,152
-25% -$2.42M
CDLX icon
50
Cardlytics
CDLX
$21.5M
$8.6M 0.66%
6,021
+487
+9% +$519K
1
2
3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Nicholas Investment Partners held 198 positions worth $1.29B, up 40% from $925M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Nicholas Investment Partners's Q4 2020 filing shows 29 new, 74 increased, 24 reduced and 25 closed positions. Its largest new stake was Arena Pharmaceuticals Inc: 276,633 shares worth $21.3M. The largest sale was Immunomedics Inc, an estimated $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Nicholas Investment Partners's largest Q4 2020 buy was Arena Pharmaceuticals Inc: 276,633 shares worth $21.3M.
  • Nicholas Investment Partners added most to TG Therapeutics in Q4 2020, an estimated $13.5M increase.
  • Nicholas Investment Partners's biggest Q4 2020 reduction was Twist Bioscience, cutting an estimated $10.1M.
  • Nicholas Investment Partners fully exited Immunomedics Inc in Q4 2020, selling an estimated $20.9M.
  • Nicholas Investment Partners's ten largest holdings make up 20% of its $1.29B portfolio in Q4 2020.
  • Nicholas Investment Partners opened 29 new positions and closed 25 in Q4 2020.
  • Nicholas Investment Partners's portfolio value rose 40% quarter-over-quarter to $1.29B.

Based on Nicholas Investment Partners's 13F filing for Q4 2020, filed 11 Feb 2021.